Overview

To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to reduce the number of new surgically eligible BCCs by 50% appearing during month 3-18 of medication ingestion.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital & Research Center Oakland
UCSF Benioff Children's Hospital Oakland
Collaborator:
Genentech, Inc.